Skip to main content

Table 2 Base case cost-effectiveness results estimated over the lifetime, discounted

From: Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

Strategies

Costs (USD)

QALYs

∆C

∆QALYs

Incremental Cost per QALY Gained (valsartan vs. enalapril)

Valsartan

119,645.45

16.15

6,625.77

0.99

6,692.69

Enalapril

113,019.68

15.16

   

Candesartan

113,093.37

15.06

Dominated

  1. QALYs = Quality-adjusted life years; ∆C = cost difference; ∆QALY = QALY difference
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us